Syndexa Pharmaceuticals Secures Investment by MP Healthcare Venture Management
Want to listen to this article for FREE?
Complete the form below to unlock access to ALL audio articles.
Read time: Less than a minute
In conjunction with the Series B1 transaction, Tetsuro Iwata will represent MPH as an Observer on Syndexa's Board of Directors.
"This funding from new investor, MP Healthcare Venture Management, and support from Tetsuro Iwata comes at an important time for Syndexa," said Teo Uysal, President and CEO. "The proceeds from our Series B1 will enable us to progress the preclinical development of our Endoplasmic Reticulum (ER) modulating compounds towards development candidate selection, and will allow us to validate the therapeutic potential of our most promising compounds in various indications of ER dysfunction."
